Posted on 10/02/2010 in Pharmaceutical Company Product News Amgen announced this week that a pivotal phase III trial evaluating denosumab against a traditional therapy in the treatment of bone metastases in men with advanced prostate cancer met both its primary and secondary endpoints.
Denosumab demonstrated superiority over the existing treatment for both delaying the time to the first skeletal-related event (SRE) - such as fracture, radiation to bone, surgery to bone or spinal cord compression - and reducing the occurrence of multiple SREs.
In particular, osteonecrosis of the jaw was infrequent and both overall survival and the time to cancer progression were found to be balanced between treatment arms.
Roger Perlmutter, executive vice-president of research and development at Amgen, said: "Denosumab has shown remarkable consistency in reducing the serious complications of bone metastases. Today's results greatly enhance our understanding of the efficacy of denosumab in multiple different tumour types."
Last month, Amgen posted its financial results for the final quarter of 2009, revealing a revenue increase of two per cent for the period. Other news stories from 10/02/2010
Read more in the Zenopa News Archive
How this news is generated
|
